Article Sidebar
Published:
Sep 16, 2014DOI:
10.4314/tjpr.v13i7.1Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Formulation of Thermosensitive Hydrogel Containing Cyclodextrin for Controlled Drug Delivery of Camptothecin
Abstract
Purpose: To formulate and evaluate temperature-sensitive, controlled-release camptothecin hydrogel for anticancer drug delivery.
Method: Temperature-sensitive hydrogel based on chitosan/β-glycerophosphate (β-GP)/β-cyclodextrin (β-CD) was prepared by crosslinking method. The formulations were characterized by Fourier transform infrared spectroscopy (FTIR), x-ray diffraction (XRD), gelation time, and viscometry, as well as for controlled release. The formulation, containing camptothecin, was studied by MTT assay on tumor cell MCF-7. The effectiveness of treatment was measured in terms of controlled tumor growth inhibition (TGI).
Results: The hydrogel formulation showed good properties in terms of pH, gelation, viscosity and invitro release. The gelation temperature and viscosity of the formulation was optimum. Camptothecin (CPT) released from the hydrogel (TF8) over 8 h in pH 7.4 buffer ranged from 38.97 - 92.5 %, and varied according to the composition of the hydrogels. Release of camptothecin was lowest from preparations without cyclodextrins. Tumor growth inhibition activity of CPT in MCF-7 cell was highest for the formulation containing 1 % chitosan, 8 % β-GP and 1 % β-CD while no inhibition was observed for the blank temperature sensitive hydrogel formulation.
Conclusion: These formulations are a promising and more effective delivery system that can be developed to serve as an alternative to the conventional system for anticancer drug delivery.
Keywords: Hydrogel, Chitosan, β-Glycerophosphate, β-Cyclodextrin, Camptothecin, MCF-7 cell line
